JP2002504100A - 肝腫瘍の治療方法およびそれに使用するための医薬組成物 - Google Patents
肝腫瘍の治療方法およびそれに使用するための医薬組成物Info
- Publication number
- JP2002504100A JP2002504100A JP50114299A JP50114299A JP2002504100A JP 2002504100 A JP2002504100 A JP 2002504100A JP 50114299 A JP50114299 A JP 50114299A JP 50114299 A JP50114299 A JP 50114299A JP 2002504100 A JP2002504100 A JP 2002504100A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- cancer
- compound
- liver
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 208000014018 liver neoplasm Diseases 0.000 title claims description 8
- 206010019695 Hepatic neoplasm Diseases 0.000 title claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 239000011710 vitamin D Substances 0.000 claims abstract description 85
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 61
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 60
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 60
- 229940046008 vitamin d Drugs 0.000 claims abstract description 60
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 44
- -1 vitamin D compound Chemical class 0.000 claims abstract description 34
- 210000004185 liver Anatomy 0.000 claims abstract description 27
- 210000002767 hepatic artery Anatomy 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 28
- 238000001802 infusion Methods 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 10
- 239000002207 metabolite Substances 0.000 claims description 10
- 102000009310 vitamin D receptors Human genes 0.000 claims description 8
- 108050000156 vitamin D receptors Proteins 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 229960001603 tamoxifen Drugs 0.000 claims description 5
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 238000011394 anticancer treatment Methods 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000011571 secondary malignant neoplasm Diseases 0.000 claims description 3
- 229940102550 Estrogen receptor antagonist Drugs 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000003240 portal vein Anatomy 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 30
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 238000001361 intraarterial administration Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- 208000037147 Hypercalcaemia Diseases 0.000 description 17
- 230000000148 hypercalcaemia Effects 0.000 description 17
- 208000030915 hypercalcemia disease Diseases 0.000 description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- 239000011575 calcium Substances 0.000 description 13
- 229910052791 calcium Inorganic materials 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000010579 first pass effect Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 5
- 235000020964 calcitriol Nutrition 0.000 description 5
- 239000011612 calcitriol Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960002882 calcipotriol Drugs 0.000 description 4
- 229960005084 calcitriol Drugs 0.000 description 4
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000000439 tumor marker Substances 0.000 description 4
- 241000282887 Suidae Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000668 effect on calcium Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000010491 poppyseed oil Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 101100129922 Caenorhabditis elegans pig-1 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101100520057 Drosophila melanogaster Pig1 gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000035563 calcemia Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229940097712 calcijex Drugs 0.000 description 1
- 229940111194 calcitriol injection Drugs 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000000121 hypercalcemic effect Effects 0.000 description 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 231100001106 life-threatening toxicity Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000032349 type 2B vitamin D-dependent rickets Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO7270A AUPO727097A0 (en) | 1997-06-10 | 1997-06-10 | Method of treatment of hepatoma and pharmaceutical compositions for use therein |
| AU7270 | 1997-06-10 | ||
| PCT/AU1998/000440 WO1998056387A1 (en) | 1997-06-10 | 1998-06-10 | Method of treatment of liver tumours and pharmaceutical compositions for use therein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002504100A true JP2002504100A (ja) | 2002-02-05 |
| JP2002504100A5 JP2002504100A5 (https=) | 2005-12-22 |
Family
ID=3801562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50114299A Withdrawn JP2002504100A (ja) | 1997-06-10 | 1998-06-10 | 肝腫瘍の治療方法およびそれに使用するための医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6486144B1 (https=) |
| EP (1) | EP1003523A4 (https=) |
| JP (1) | JP2002504100A (https=) |
| KR (1) | KR100382219B1 (https=) |
| CN (1) | CN1154497C (https=) |
| AU (1) | AUPO727097A0 (https=) |
| WO (1) | WO1998056387A1 (https=) |
| ZA (1) | ZA985028B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505881A (ja) * | 2003-09-19 | 2007-03-15 | ファイザー・プロダクツ・インク | ２−アルキリデン−１９−ノル−ビタミンｄ誘導体およびエストロゲンアゴニスト／アンタゴニストの組合せを含む医薬組成物および方法 |
| JP2016124818A (ja) * | 2014-12-26 | 2016-07-11 | 日本化薬株式会社 | 転移性肝癌治療薬及び転移性肝癌の治療方法 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6538037B2 (en) | 1991-01-08 | 2003-03-25 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
| US6573256B2 (en) | 1996-12-30 | 2003-06-03 | Bone Care International, Inc. | Method of inhibiting angiogenesis using active vitamin D analogues |
| US6566353B2 (en) | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
| US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US6087350A (en) | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| AUPP332898A0 (en) * | 1998-05-04 | 1998-05-28 | Unisearch Limited | Pharmaceutical composition |
| AU765846B2 (en) * | 1998-05-04 | 2003-10-02 | Mrc Holdings Pty Limited | Pharmaceutical composition |
| US20030031670A1 (en) * | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
| AU1917101A (en) * | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| DE10032587A1 (de) * | 2000-07-05 | 2002-01-17 | Bayer Ag | 4-Alkoxy-cyclohexan-1-amino-carbonsäureester und Verfahren zu ihrer Herstellung |
| AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| WO2002076454A1 (en) * | 2001-03-26 | 2002-10-03 | Unisearch Limited | Method for treatment of cancer and compositions for use therein |
| JP2004026811A (ja) * | 2002-04-30 | 2004-01-29 | Kiyoshi Hashizume | ビタミンｄ３誘導体を含有する抗癌作用を増強させるための薬剤 |
| AU2002330482A1 (en) | 2002-09-04 | 2004-03-29 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
| WO2004047673A2 (en) * | 2002-11-21 | 2004-06-10 | Novacea, Inc. | Treatment of liver disease with active vitamin d compounds |
| WO2005027918A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor |
| WO2005027928A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism |
| WO2005027922A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of hypogonadism or andropause |
| WO2005027916A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors |
| US7094775B2 (en) | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| JP4248544B2 (ja) * | 2005-12-19 | 2009-04-02 | 株式会社椿本チエイン | 伝動装置用可動ガイド |
| CN102655869B (zh) * | 2009-08-14 | 2016-08-10 | 博格有限责任公司 | 用于治疗脱发的维生素d3及其类似物 |
| CN105473147A (zh) | 2013-04-24 | 2016-04-06 | 萨克生物研究学院 | 维生素d受体/smad基因组回路门纤维化反应 |
| WO2014197680A1 (en) * | 2013-06-05 | 2014-12-11 | Salk Institute For Biological Studies | Vitamin d receptor agonists to treat diseases involving cxcl12 activity |
| WO2016167977A1 (en) | 2015-04-14 | 2016-10-20 | Mayo Foundation For Medical Education And Research | Methods and materials for delivering agents to liver tissue |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| CN116059364B (zh) * | 2021-11-04 | 2025-07-11 | 上海健康医学院 | Dhcr7下调剂在减弱酒精诱导的肝脏肿瘤中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3865544D1 (de) | 1987-06-23 | 1991-11-21 | Yamanouchi Pharma Co Ltd | Vitamin d3-derivate. |
| US4927815A (en) * | 1988-04-29 | 1990-05-22 | Wisconsin Alumni Research Foundation | Compounds effective in inducing cell differentiation and process for preparing same |
| US5798345A (en) | 1990-09-21 | 1998-08-25 | Bone Care International, Inc. | Method of inhibiting the hyperproliferation of malignant cells |
| RU2153491C2 (ru) * | 1993-07-09 | 2000-07-27 | Лаборатуар Терамекс С.А. | Аналоги витамина d, соединения, способы их получения и фармацевтическая композиция |
| US5856189A (en) * | 1997-01-07 | 1999-01-05 | The Regents Of The University Of Michigan | Cell culture model for drug bioavailability |
-
1997
- 1997-06-10 AU AUPO7270A patent/AUPO727097A0/en not_active Abandoned
-
1998
- 1998-06-10 US US09/445,688 patent/US6486144B1/en not_active Expired - Fee Related
- 1998-06-10 JP JP50114299A patent/JP2002504100A/ja not_active Withdrawn
- 1998-06-10 ZA ZA985028A patent/ZA985028B/xx unknown
- 1998-06-10 CN CNB988067609A patent/CN1154497C/zh not_active Expired - Fee Related
- 1998-06-10 EP EP98923934A patent/EP1003523A4/en not_active Withdrawn
- 1998-06-10 WO PCT/AU1998/000440 patent/WO1998056387A1/en not_active Ceased
- 1998-06-10 KR KR10-1999-7011663A patent/KR100382219B1/ko not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505881A (ja) * | 2003-09-19 | 2007-03-15 | ファイザー・プロダクツ・インク | ２−アルキリデン−１９−ノル−ビタミンｄ誘導体およびエストロゲンアゴニスト／アンタゴニストの組合せを含む医薬組成物および方法 |
| JP2016124818A (ja) * | 2014-12-26 | 2016-07-11 | 日本化薬株式会社 | 転移性肝癌治療薬及び転移性肝癌の治療方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US6486144B1 (en) | 2002-11-26 |
| HK1030144A1 (en) | 2001-04-27 |
| CN1154497C (zh) | 2004-06-23 |
| AUPO727097A0 (en) | 1997-07-03 |
| ZA985028B (en) | 1999-01-25 |
| EP1003523A1 (en) | 2000-05-31 |
| CN1261800A (zh) | 2000-08-02 |
| WO1998056387A1 (en) | 1998-12-17 |
| KR20010013651A (ko) | 2001-02-26 |
| KR100382219B1 (ko) | 2003-04-26 |
| EP1003523A4 (en) | 2001-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002504100A (ja) | 肝腫瘍の治療方法およびそれに使用するための医薬組成物 | |
| JP5137293B2 (ja) | 親油性の薬剤のための組成物 | |
| EP0109564B1 (en) | The use of gallium salts for the manufacture of pharmaceutical compositions for the treatment of disorders of calcium homeostasis | |
| CN104523707B (zh) | 包含维生素d化合物和蜡质载体的口服控释组合物 | |
| KR20000062405A (ko) | 지연방출성 및/또는 서방출성 비타민 ｄ 제형을 사용하여 전립선 질환을 치료하는 방법 | |
| BR112019018880A2 (pt) | composições de plinabulina e seu uso | |
| JPS6245845B2 (https=) | ||
| JP2002516307A (ja) | １α−ヒドロキシ−２５−エン−ビタミンＤ、類似体及びその使用 | |
| WO2008067060A2 (en) | Formulations for treatment of adipose tissue, cutaneous tissue and disorders, and muscular tissue | |
| JPH05508155A (ja) | ヒト前立腺腺癌の治療方法 | |
| US20080207769A1 (en) | Method for treating benign prostatic hyperplasia | |
| KR20030090673A (ko) | 에스트로겐 대체 요법 | |
| WO2007036802A2 (en) | Sublingual dosage form comrising vitamin d analogue, in particular calcitriol | |
| JP2003511348A (ja) | 可溶化された非経口投与用の医薬組成物 | |
| JPH01301623A (ja) | にきびまたはアンドロゲン性脱毛の局所治療のためのエチステロンの使用 | |
| US6664246B2 (en) | Pharmaceutical composition | |
| JP2002513733A5 (https=) | ||
| WO2005027923A1 (en) | Use of vitamin d3 analogue for the treatment of benign prostatic hyperplasia | |
| AU735676B2 (en) | Method of treatment of liver tumours and pharmaceutical compositions for use therein | |
| EP1698332A1 (en) | Oral modified release formulations containing 8-Prenylnaringenin for continuous estrogen support | |
| JP2003523929A (ja) | 時間的に制御される医薬作用を有する口腔内適用可能な生体接着系を製造するためのテストステロンエステルおよび／またはテストステロンの使用 | |
| FLASHNER-BARAK et al. | International patent for sublingual liquid analogue forms of vitamin D–2007 | |
| US20030186954A1 (en) | Estriol to treat and prevent cardiovascular disease | |
| Calvey et al. | G. Seyffart, Drug Dosage in Renal Insufficiency© Kluwer Academic Publishers 1991 | |
| HK1030144B (en) | Method for treatment of liver tumours and pharmaceutical compositions for use therein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050606 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050606 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080423 |